Author

Chloe F. Allen

University of SheffieldORCID 0000-0002-3333-7246Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

Allan Christian ShawiD· 2 shared Laura FerraiuoloiD· 2 shared Monika A. MyszczynskaiD· 2 shared Raquel Rua MartinsiD· 2 shared Richard J. MeadiD· 2 shared Tyler R. WellsiD· 2 shared Alex Daniel· 1 shared Amy F. A. KeerieiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Allan Christian ShawORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Artificial intelligence-augmented drug discovery identifies gefitinib as a potential treatment for ALS

Monika A. Myszczynska, Matthew J. Stopford, Nóra M. Márkus, Sophie Nyberg, Nicole L. Stone, Sarah M. Granger, Allan Christian Shaw, Raquel Rua Martins, Chloe F. Allen, Amy F. A. Keerie, Tyler R. Wells, Ruth H.E. Thomas, Heledd Brown-Wright, David W. Sheppard, Anne Phelan, , Laura Ferraiuolo

This paper uses AI to identify gefitinib as a potential ALS treatment, showing it protects motor neurons and reduces TDP-43 fragments in vitro and in vivo.

bioRxiv · Mar 6, 2025 · PreprintNeuroscience

M102, a combined NRF2 and HSF-1 activator for neuroprotection in amyotrophic lateral sclerosis.

Amy F. Keerie, Raquel Rua Martins, Chloe F. Allen, Katie M Bowden, Sufana Al Mashhadi, Thomas R. Marlow, Monika A. Myszczynska, Nikitha Thakur, Selina N. Beal, Allan Christian Shaw, Shivani Suresh, Scott N. McKinnon, Alex Daniel, Tyler R. Wells, Ira N. Kalfus, , Richard J. Mead

M102, a dual NRF2/HSF1 activator, slows disease progression in 2 mouse models and exerts neuroprotection in human cellular models of ALS.

bioRxiv · Dec 8, 2024 · PreprintNeuroscience